ABSTRACT. IgE-binding factors are thought to have regulatory activity in in vitvo IgE synthesis. To obtain evidence of the participation of IgE-binding factors in in vivo IgE synthesis, the serum level of low affinity Fc receptors for IgE (sFceRI1) (IgE-BFs) was examined in 41 nonallergic children and in 37 allergic children whose serum IgE levels were significantly higher than those of nonallergic children. The serum level of sFctRII showed a marked age-dependent variation. It was highest in infants and then decreased gradually with age. The serum level of sFctRII in allergic children was significantly higher than that of nonallergic children in early childhood (1128.0 f 323.8 vs 777.3 2 227.0 pg/ml, p < 0.01 in infants (<I y) and 851.8 + 270.0 vs 579.4 2 197.1 pg/ml, p < 0.05 in children aged 1-2 y) but not in older children (3-15 y). Three allergic infants (<I y) with serum sFctRII levels higher than the mean + 1 S D (1451.8 pg/ml) of all allergic infants (<I y) had serum IgE levels (geometric mean 125.9 IU/ml) significantly higher than the other seven allergic infants (<I y) (geometric mean 5.6 IU/ml, p < 0.05). A close positive correlation between the serum level of sFctRII and the absolute number of FctRII(+) peripheral blood lymphocytes was observed (Spearman's rank correlation coefficient = 0.79, p < 0.001 in 27 allergic and Spearman's rank correlation coefficient = 0.72, p < 0.001 in 19 nonallergic children). In conclusion, serum sFctRII may be derived mainly from FctRII(+) lymphocytes, and may have relationship to the increased production of IgE in early childhood (0-2 y). (Pediatv Res 26: 49-53, 1989) Abbreviations FctRII, low affinity Fc receptors for IgE IgE-BF, IgE-binding factor MNC. mononuclear cells former is produced by FctRII(+) T lymphocytes, and the latter is produced by FctRII(-) T lymphocytes (6). Human FctRII(+) T lymphocytes can secrete IgE-potentiating factor (7-10). Recently, FctRII(+) B lymphocytes, which are more numerous than FctRII(+) T lymphocytes (1 I, 12), have also been shown to be capable of producing IgE-potentiating factor (1 3-15). Thus, FctRII(+) B lymphocytes, as well as FctRII(+) T lymphocytes, appear to be involved in the regulation of IgE synthesis.
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With the use of FctRII(+) human B lymphoblastoid cell lines (RPMI1788, RPMI8866), several anti-FctRII mAb have been produced (16) (17) (18) (19) . It is now easy to detect not only FctRII, but also IgE-BF because of their common antigenic determinants to FctRII (20, 2 1). The production of the mAb was followed by the determination of the gene structure of FctRII (22) (23) (24) , which in turn enabled its more precise molecular analysis. FctRII was demonstrated to be the same molecule as the CD23 Ag (19, 25) . The IgE-BF obtained from the supernatants of FctRII(+) T and B cell lines was demonstrated to be the soluble form of FctRII (sFctRII) released by cleavage of the polypeptide chain (15, 26, 
L I ).
The serum IgE level is often increased in allergic individuals (28) . The proportion of FctRII(+) lymphocytes has been shown to be increased in allergic patients and in those with nonallergic hyper-IgE conditions (29-3 1). This suggests that FctRII(+) lymphocytes participate in the regulation of in vivo IgE synthesis by the production of sFctRII. If sFctRII actually plays a role in the in vivo synthesis of IgE, its serum level should be significantly different between allergic and nonallergic individuals. With this assumption, we investigated the serum level of sFctRII in allergic and nonallergic children because the elevation of the percentage of FctRII(+) lymphocytes, which release sFctRII, is detected much more easily in allergic children than in allergic adults (3 1).
MATERIALS AND METHODS
RAST, radioallergosorbent test rs, Spearman's rank correlation coefficient Donors. Allergic disorders were diagnosed when children with sFctRI1, soluble form of FctRII typical symptoms showed positive results in RAST or skin tests and/or elevated serum IgE levels higher than the geometric mean -t 1 SD of those of nonallergic children in this study. In actual practice these levels were set at 10 IU/ml in infants, 100 IU/ml in 1-to 2-y-old children and 400 I U /~I in older children (3-15 It has been demonstrated in rodents that IgE production is Y). regulated by IgE-BF (1-3). IgE-BF are glycoprotein molecules
The allergic group consisted of 37 children (25 males and 12 with afiinity for IgE (4, 5 ) consisting of two functionally different females); 15 had atopic dermatitis, 14 had bronchial asthma, and components: one enhances IgE synthesis (IgE-potentiating fac-8 had both. Among them, 33 (89.1%) had a positive family tor) (2) , and the other inhibits it (IgE-suppressive factor) (3). FctR1l(+) = count lymphocytes lymphocytes sFctRII determination were stored at -40°C until the examina-lymphocytes (l/mrn3) 1100 1100 tion. Under this condition, the value of serum sFctRII was stable (1/mm3) for at least 1 y.
Measurement of serum IgE levels. Serum IgE levels were examined by Pharmacia IgE RIA kits (Pharmacia Fine Chemicals, Uppsala, Sweden), which were generously provided by Shionogi & Company Ltd., Osaka, Japan. The measurable range is 10-2,000 IU/ml with the standard procedure, and 1 to 40 IU/ ml with the high sensitivity procedure.
Determination of serum sFctRII. sFctRII was measured by the solid phase sandwich ELISA method described previously (1 5). Two mouse anti-human FctRII mAb, which recognized different epitopes, were applied to the assay. One was the H107 antibody (18) and the other was the mAb 176 antibody which was kindly provided by Dr. G. Delespesse of the University of Montreal, Quebec, Canada (16) . Both the H 107 and Mab176 antibodies are demonstrated to react with sFctRII derived from FctRII(+) T and B lymphocytes (15, 27) . This assay system is also able to detect sFctRII derived from a human monoblastic cell line U937 (1 5) and a human eosinoleukemic cell line EoL (M. Hosoda and J. Yodoi, unpublished data).
Briefly, 2 pg/ml of mAb176 antibody in NaOH-NaHC03 solution (pH 9.0) was delivered into a polystyrene microplate (Immuno plate I, Nunc, Roskilde, Denmark) in a volume of 50 pl/well and incubated overnight at 4°C. Residual binding sites of the solid phase were blocked by 150 p1 of ELISA solution (10 mM PBS containing 2% BSA and 0.05% Tween 20) in each well. After incubation overnight at 4"C, a 50 p1 sample was placed in each well in triplicate and incubated overnight at 4°C. Then, 50 p1 of alkaline phosphatase VII-S (Sigma Chemical Co., St. Louis, MO) coupled H107 antibody in ELISA solution (0.4 pg/ml) was put into each well and incubated for 4 h at 4°C. Finally, 100 p1 of enzyme substrate solution (1 tablet of phosphatase substrate (Sigma) per 5 ml substrate buffer) was placed in each well. Then 1 liter of substrate buffer, pH 9.8, contained 97 ml of diethanolamine, 100 mg of MgC12.6 Hz0 and 200 mg of NaN,. Plates were washed vigorously five times with washing solution (PBS containing 0.05% Tween 20) after the completion of each incubation.
The enzyme activity bound to the solid phase was determined by reading the absorbance at a wave-length of 405 nm with an automated photometer (MTP12, Corona Electric Co Ltd, Ibaragi, Japan). Standard human sFctRII was collected and purified from the supernatant of RPMI 8866 cells (23) .
Absolute number of FctRII(+) lymphocytes. The procedure to determine the percentage of FctRII(+) PBL was described previously (3 1). Briefly, heparinized blood was incubated with silica particles (KAC2, Japan Immunoresearch Laboratories, Takasaki, Japan) to remove monocytes/phagocytes. MNC were obtained by centrifugation over Ficoll-Paque (Pharmacia) (34) . MNC were incubated with 20 of 20 pg/ml H107 antibody (first incubation), and then with 20 p1 of 20 pg/ml FITCconjugated anti-mouse IgG antibody (Tago Inc., Burlingame, CA) (second incubation) at 4°C for 30 min. A negative control for each sample was prepared by the same procedure except that 20 p1 of 20 pg/ml non-related purified mouse myeloma IgG2b protein (Miles Scientific, Naperville, IL), which is the same class as the H 107 antibody, was used at the first incubation instead of the HI07 antibody. The percentage of fluorescence-positive cells in the lymphocyte population was determined by flow cytometry (FACS 440, Becton Dickinson Labware, Mountain View, CA). The difference in the percentage of fluorescence-positive cells between the sample and each negative control sample was reAnalysis of data. Data on the serum sFctRII were presented as the mean f 1 SD. Data on the serum IgE were first transformed logarithmically, and then presented as the geometric mean and a range of 1 SD (28) . The statistical significance of the difference in serum sFctRII levels was evaluated by a t-test. The statistical significance of the difference in serum IgE levels and the absolute number of FctRII(+) lymphocytes was evaluated by Wilcoxon's rank-sum test. The correlation of serum sFctRII and serum IgE levels or the absolute number of FctRII(+) lymphocytes was evaluated by rs. For convenience in calculation, serum IgE levels lower than 1 IU/ml were all approximated at 0.5 IU/ ml.
RESULTS
Serum level of sFctRII. The serum level of sFctRII varies considerably with age in both allergic and nonallergic children. It was highest in infants and decreased gradually with age, reaching the adult level at about 8 y of age and then remaining constant. For statistical purposes, children were divided into four age groups, I, 11, 111, and IV, aged <1, 1-2, 3-7, and 8-1 5 y, respectively ( Table 1 ). The mean + 1 SD of age in allergic and nonallergic group I was 5.0 f 2.3 and 4.5 a 3.3 mo, respectively. Allergic children in groups I and I1 had significantly higher levels of serum sFctRII than their nonallergic counterparts (p < 0.01 and 0.05, respectively) (Table 1) . However, significant differences in the serum levels of sFctRII between allergic and nonallergic individuals were no longer observed in groups I11 and IV or in adults.
The serum sFccRII was not affected by sex, medication with anti-allergic or anti-asthmatic agents, or type or severity of diseases (data not shown).
Correlation of sFccRII with serum IgE. The serum level of IgE in allergic children was significantly higher than in nonallergic children in all age groups (Table 2) .
Generally, the correlation between the serum levels of sFcrRI1 and of IgE was poor. The serum level of sFctRII tended to correlate negatively rather than positively with the serum level of IgE in both allergic and nonallergic individuals.
However, in allergic group I, three children, who had serum sFctRII levels higher than the mean + 1 SD (145 1.8 pg/ml), also had significantly higher serum IgE (mean 125.9 IU/ml; 1 SD range 3 1.6-501.2 IU/ml) than the other seven children (5.6 IU/ ml; 1.2-26.3 IU/ml: p < 0.05).
Correlation of serum sFctRII with absolute number of FctRII(+) PBL. In nonallergic children, although the percentage of FctRII(+) PBL was constant in all age groups, their absolute number showed a marked age-dependent variation similar to that of serum sFctRII (Table 3) . It was highest in infants, and thereafter decreased with age. Both the absolute number of FctRII(+) lymphocytes and the percentage of FctRII(+) lymphocytes were significantly higher in allergic children of groups I and I1 than in their nonallergic counterparts ( p < 0.05 and <0.01, respectively), whereas there was no significant difference between allergic and nonallergic children of groups 111 and IV (Table 3) . The absolute lymphocyte count did not differ significantly between allergic and nonallergic children in each age-group (data not shown).
The relationship between the serum level of sFctRII and the absolute number off FctRII(+) lymphocytes was analyzed in 27 allergic and 19 nonallergic children. As shown in Figure 1 , a significant positive correlation was demonstrated in both allergic and nonallergic individuals (rs = 0.79, p < 0.001 in the allergic and rs = 0.72, p < 0.00 1 in the nonallergic).
DISCUSSION
The serum level of sFceRII showed a marked age-dependent variation in both allergic and nonallergic children and had a close positive correlation with the absolute number of FctRII(+) lymphocytes. Because the percentage of FctRII(+) cells in PBL is constant irrespective of age, except in allergic younger children (Table 3 ), the age-dependent variation of the absolute number of FctRII(+) lymphocytes is likely to reflect the total lymphocyte count. Therefore, the age-dependent variation of serum sFctRII of nonallergic children as well as of allergic older children may be due mainly to the physiologic age-dependent variation of the absolute number of lymphocytes. However, the increase in the serum level of sFctRII and in the absolute number of FctRII(+) lymphocytes in allergic younger children is due not to an increase in the total number of lymphocytes but to the increased percentage of FctRII(+) lymphocytes (Table 3) .
FctRII are expressed not only on lymphocytes, but also on monocytes/macrophages, eosinophils, and platelets (35) (36) (37) . Inasmuch as most sFctRII, if not all, is a degradation product of cell surface FccRII (15, 26, 27) , blood cells other than lymphocytes may also release sFctRII into the serum. However, because the pattern of the age-dependent variation of lymphocytes is unique to them and different from that of the other blood cells (38) , it appears that FctRII(+) blood cells other than lymphocytes do not influence significantly the serum level of sFctRII; i.e., most of the serum sFctRII is probably derived from FctRII(+) lymphocytes.
Although two functionally different IgE-BF, IgE-potentiating and IgE-suppressive factor, were noted in a rodent model for IgE synthesis (2, 3) , only IgE-potentiating activity is described for human IgE-BF derived from FctRII(+) B cells (13, 14) . Because most FctRII(+) PBL are B cells (31) , the majority of serum sFctRII may be a product of FctRII(+) B cells. Therefore, serum sFctRII is assumed to be an IgE-potentiating factor. Generally speaking, however, serum sFctRII did not correlate with the serum IgE level. Although one of the most remarkable features of the serum level of sFctRII is its age-dependent variation, it did not resemble that of the serum IgE level. Moreover, no significant difference of serum sFctRII between allergic and nonallergic individuals of older age-groups was observed despite the significant difference of the serum IgE level. These results indicate that all serum sFctRII cannot be an IgE-potentiating factor. sFctRII may consist of multiple components with different functions, as has been shown in rodents (2, 3) .
However, the biologic significance of sFctRII cannot be denied entirely because the serum levels of sFctRII and of IgE in allergic younger children (age groups I and 11) were significantly higher than in nonallergic younger children. Moreover, in allergic group I, children with very high levels of serum sFctRII also had significantly higher serum IgE levels than the other children. These findings suggest that sFctRII is related in some way to increased IgE synthesis, at least in younger allergic children.
The reason for the elevation of serum sFctRII in allergic younger children only is unknown. However, it is not diseaserelated because in group I1 (1-2 y) seven children had atopic dermatitis, two had bronchial asthma and two had both; their serum levels of sFctRII were 861.4 + 272.5, 885.0 f 365.0, and 785.0 + 45.0 pg/ml, respectively.
Recently, some lymphokines, such as IL-4 and IFN-7 have attracted attention as regulatory factors not only of the expression of FctRII or the release of sFctRII but also of the IgE synthesis itself (22, (39) (40) (41) (42) ; IL-4 enhances and IFN-7 suppresses these reactions. The serum level of sFctRII as well as that of IgE might be affected by these lymphokines. However, we have little knowledge about the behavior of these lymphokines in allergic and nonallergic children, although the inability of T cells to produce IFN-7 has been noted in neonates (43, 44) . Advances in the study of these lymphokines, as well as of sFccRII, may provide a solution to this problem.
The elevation of serum sFctRII in allergic younger children seems to be determined congenitally to some extent. In a study which aims to pinpoint neonates at high risk for developing atopic diseases by the serum level of sFctRII in cord blood, our preliminary data show that infants who later develop atopic symptoms have a significantly higher cord serum sFccRII than those who remain free of atopic symptoms (593.7 + 334.4 vs 393.8 + 174.8, p < 0.01 at 7 mo of age) (Kim KM, et al.
unpublished data).
The measurement of serum IgE is an important laboratory test in the diagnosis of allergic disorders. However. in vounger , < children the s&um IgE level-is often too low to be detectedvby routine assay systems. On the contrary, sFctRII is easily measured even in cord blood. For clinical purposes, serum sFctRII, along with other tests, may prove to be of value in diagnosing allergic disorders in early childhood.
